



**Pedro Barata Coelho** is a Medical Doctor working in Clinical Pathology and clinical research at ULS de Santo António - Porto, Portugal and at the Hyperbaric Unit of the ULS Matosinhos, focusing on clinical research.

He completed his Medical Degree at Faculdade de Medicina da Universidade do Porto. He also holds a

PhD in Pharmaceutical Sciences from Faculdade de Farmácia da Universidade do Porto, where he completed his MSc and PharmD. Additionally, he completed the Global Clinical Scholars Research Training program at Harvard Medical School and obtained an MBA from the Portuguese Catholic University. He also has a postgraduate degree in healthcare management.

Currently, he is an Associate Professor at Faculdade de Ciências da Saúde da Universidade Fernando Pessoa in Porto, Portugal, and a senior lecturer at various institutions, including Kings College London, Universidade de Coimbra, Universidade Nova de Lisboa, and Universidade do Porto.

He is a member of the Medicines Evaluation Commission of Infarmed, the Portuguese regulatory authority, and a quality expert for the European Medicines Agency and is the Vice-President of the National Ethics Commission for Clinical Research. He conducts his research at Rise Health, a prominent Portuguese research centre, focusing on the clinical effects of Hyperbaric Oxygen Therapies, Mitochondria, and Gut Microbiome.

He has published numerous papers and received scientific awards, including winning the Zetterstrom Award twice with the ULS Matosinhos team. He is a member of the team that received EUBS research grant 2024 and supervised several PhD students and Master theses. He was a member of the organizing and scientific committee for EUBS 2023, which was held in Porto - Portugal.